Brief: Herantis Announces Follow-Up Review From Phase 1 Lymfactin Trial In Breast Cancer-Associated Lymphedema

Herantis Pharma Oyj

23/04/2019 07:43

April 23 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * ANNOUNCES 12-MONTH FOLLOW-UP REVIEW FROM PHASE 1 LYMFACTIN
TRIAL
IN BREAST CANCER-ASSOCIATED LYMPHEDEMA
    * HERANTIS PHARMA  - DATA MONITORING COMMITTEE CONCLUDED
THAT
TREATMENT CONTINUES TO BE SAFE AND WELL-TOLERATED IN ALL
PATIENTS WITH NO SEVERE ADVERSE EVENTS

Source text for Eikon:  ID:nGNE9BlJWs 
Further company coverage:  HRTIS.HE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))